… 10 (LCA10). Presentation title : Proof-of-concept for RNA-editing oligonucleotide QR-110 for treatment of inherited … clinical studies Poster presentation on Axiomer ® RNA editing technology A presentation will be delivered by … computational analytics of ProQR on the Axiomer ® RNA editing technology. Poster title: Structure-based …
… with LCA10 and preclinical data for ProQR’s Axiomer ® RNA-editing technology. Abstract titles: ○ Proof-of-concept for RNA-editing oligonucleotide QR-110 for treatment of inherited … ® EONs are designed to recruit an endogenously expressed RNA editing system called ADAR, which it can direct to the …
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w
LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022
Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing pla